Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01421134 · ClinicalTrials.gov registry record · Phase 3
Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
A Phase 3 study of Major Depressive Disorder With Mixed Features, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 211
- Enrollment target
- 20
- Study locations
NCT01421134 is a Phase 3 study of Major Depressive Disorder With Mixed Features that has completed, run by Sumitomo Pharma America. The registered enrollment target is 211 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT01421134, a Phase 3 study of Major Depressive Disorder With Mixed Features, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 211 participants
- Enrollment target
- 20
- Study locations
Study Summary
Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lurasidone
Study Locations (20)
California
- Synergy Clinical Research Center - Escondido
- Collaborative Neuroscience Network Inc. - Garden Grove
- Stanford -VA Palo Alto Health Care System - Palo Alto
- Clinical Innovations Inc. - Riverside
- Artemis Institute for Clinical Research - San Diego
New York
- Social Psychiatric Research Inst. (SPRI) Clinical Trials - Brooklyn
- Village Clinical Research Inc. - New York
- Finger Lakes Clinical Research - Rochester
- Behavioral Medical Research of Staten Island - Staten Island
Texas
- FutureSearch Trials of Dallas, LP - Dallas
- Dept. of Psychiatry, UT Southwestern Medical Center - Dallas
- Grayline Clinical Drug Trials - Wichita Falls
Alabama
- Birmingham Psychiatry Pharmaceutical Studies, Inc. - Birmingham
Florida
- Florida Clinical Research Center, LLC - Sarasota
Massachusetts
- Massachusetts General Hospital - Center for Anxiety and Traumatic Stress Disorders - Boston
Missouri
- St. Charles Psychiatric Associates/Midwest Research Group - Saint Charles
North Carolina
- Psychiatry and Behavioral Sciences, Duke - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2011-09 |
| Est. Completion | 2014-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01421134
The ClinicalTrials.gov registry entry for NCT01421134 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 211 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder With Mixed Features appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01421134 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT01421134 about?
NCT01421134 is a clinical study titled "Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose". Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features.
What is the current status of trial NCT01421134?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 211 participants. The study started on 2011-09. Estimated completion is 2014-10.
What conditions does trial NCT01421134 study?
This clinical trial studies the following conditions: Major Depressive Disorder With Mixed Features.
What interventions are being tested in trial NCT01421134?
The interventions under investigation include: Placebo (DRUG), Lurasidone (DRUG).
Who is sponsoring clinical trial NCT01421134?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01421134 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.